Clinical Trial Update: Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial combining volasertib with vincristine sulfate liposome for relapsed or refractory adult acute lymphoblastic leukemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Vincristine sulfate liposome (vincristine sulfate liposome)
• Volasertib (Volasertib)

Snippet

Sponsor: Northwestern University | Conditions: Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia | Phase 1 | Status: WITHDRAWN